The CRISPR Revolution: How Genomic Engineering is Transforming Cancer Immunotherapy

In this episode of our “Cancer Immunotherapy and You” patient education webinar series, Dr. Alexander Marson—a CRI Lloyd J. Old STAR at the University of California, San Francisco (UCSF), the Gladstone-UCSF Institute of Genomic Immunology, and the Innovative Genomics Institute—explores how CRISPR genetic engineering tools are helping to advance the field of cancer immunotherapy and improve care for patients.

This webinar, hosted by Dr. Arthur Brodsky, CRI’s associate director of scientific content, is sponsored by CRISPR Therapeutics and Alkermes.

Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers.

Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.